Camurus : 2021-05-10 Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence

PRESS RELEASE
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine
The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment
Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life
Lund, Sweden - 10 May 2021 - Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal®) versus daily sublingual buprenorphine.

Related Keywords

Australia ,Sweden ,Stockholm ,Swedish ,Fredrik Joabsson ,Fredrik Tiberg ,Buvidal Weeklyand ,United Nations ,Business Development ,Depot Evaluation ,Utilisation Trial ,Treatment Satisfaction Questionnaire ,Product Characteristics ,Australian Product ,European Medical Agency ,Medical Products ,Human Use ,Nasdaq Stockholm ,Reported Outcomes ,Opioid Dependence With Weekly ,Monthly Subcutaneous Depot ,Daily Sublingual ,Randomized Clinical ,Drug Report ,Chief Business Development Officer ,ஆஸ்திரேலியா ,ஸ்வீடந் ,ஸ்டாக்‌ஹோல்ம் ,ஸ்விட்ச் ,ஒன்றுபட்டது நாடுகள் ,வணிக வளர்ச்சி ,டிப்போ மதிப்பீடு ,ப்ராடக்ட் பண்புகள் ,ஆஸ்திரேலிய ப்ராடக்ட் ,மருத்துவ ப்ராடக்ட்ஸ் ,மனிதன் பயன்பாடு ,நாஸ்டாக் ஸ்டாக்‌ஹோல்ம் ,மருந்து அறிக்கை ,தலைமை வணிக வளர்ச்சி அதிகாரி ,